Can NyQuil (containing diphenhydramine and doxylamine) prolong the QTc interval?

Can NyQuil Prolong the QTc Interval?

Yes, NyQuil can prolong the QTc interval, but only in overdose or supratherapeutic exposures—not at recommended therapeutic doses. The formulation containing doxylamine (NyQuil Severe) and diphenhydramine (standard NyQuil) both carry this risk when taken in excess, though routine ECG monitoring is not required for patients using standard over-the-counter doses without additional risk factors.

Evidence for QTc Prolongation

Diphenhydramine (Standard NyQuil Component)

• Diphenhydramine is explicitly listed as a QT-prolonging medication in the 2016 American Academy of Pediatrics guideline on acute mental health emergencies, appearing in Table 5 alongside other antihistamines such as hydroxyzine and loratadine. 1

• In overdose settings, diphenhydramine demonstrates a statistically significant association with QTc > 500 ms. A 2022 retrospective poison center study of 760 exposures to CredibleMeds "Known Risk of TdP" substances found that diphenhydramine—though not formally categorized as "Known Risk"—had a significant association with extreme QTc prolongation. 2

• The mechanism involves dual ion-channel blockade: diphenhydramine inhibits fast sodium channels at therapeutic concentrations and blocks repolarizing potassium channels (particularly IKr) at higher concentrations, leading to action potential prolongation and QTc lengthening. 3, 4

• Toxicity is dose-dependent with a critical threshold of 1.0 g. Case reports document QTc prolongation, torsades de pointes, and wide-complex tachycardia following ingestions exceeding this dose, with complete reversion to normal ECG after supportive treatment. 5, 3, 4, 6

Doxylamine (NyQuil Severe Component)

• Doxylamine is structurally and pharmacologically similar to diphenhydramine and shares the same antihistamine class (ethanolamine derivatives), suggesting comparable cardiac effects in overdose, though specific QTc data for doxylamine are limited in the provided evidence. 7

Risk Stratification for NyQuil Use

Low-Risk Scenario (No ECG Required)

• Therapeutic dosing in otherwise healthy adults without additional risk factors does not require baseline ECG monitoring. The 2023 Canadian Cardiovascular Society guideline states that routine ECG is not needed when prescribing standard diphenhydramine doses (25–50 mg) to patients without high-risk features. 8

High-Risk Scenario (ECG Mandatory)

Obtain a baseline ECG with manual QTc measurement before NyQuil use when any of the following are present: 8

• Baseline QTc > 480 ms or known congenital long QT syndrome
• Concurrent use of another QT-prolonging drug (macrolides, fluoroquinolones, citalopram/escitalopram, antipsychotics, methadone, ondansetron)
• Severe electrolyte disturbance (K⁺ < 3.5 mmol/L, Mg²⁺ < 1.5 mg/dL, hypocalcemia)
• Multiple risk factors: female sex, age > 60 years, structural heart disease, bradycardia, diuretic use, renal impairment

Management of Suspected NyQuil-Related QTc Prolongation

Immediate Actions (QTc ≥ 500 ms or Symptomatic)

1. Discontinue NyQuil immediately and initiate continuous cardiac telemetry. 8
2. Correct electrolytes urgently: target K⁺ > 4.5 mmol/L, Mg²⁺ > 2.0 mg/dL, normalize calcium. 8
3. If torsades de pointes occurs: administer IV magnesium sulfate 2 g regardless of serum level, correct bradycardia with temporary pacing or isoproterenol, and avoid amiodarone or procainamide. 8

Post-Acute Evaluation

• Repeat ECG after five drug half-lives (approximately 24–48 hours for diphenhydramine) and after electrolyte normalization. 8
• If QTc normalizes to < 450 ms (men) or < 460 ms (women), the diagnosis is acquired long QT syndrome; genetic testing is not required. 8
• If QTc remains > 480 ms despite correction, suspect congenital long QT syndrome and refer to an inherited arrhythmia clinic. 8

Safer Alternatives for Sleep and Cold Symptoms

• For sleep: mirtazapine 7.5–30 mg at bedtime or low-dose quetiapine 25–100 mg have lower hERG affinity and minimal QT risk compared to diphenhydramine. 8
• For nasal congestion: intranasal corticosteroids (fluticasone, mometasone) or saline irrigation carry no cardiac risk.
• For cough: dextromethorphan (the antitussive component in NyQuil) is not associated with QT prolongation and can be used alone.

Critical Pitfalls to Avoid

• Do not assume over-the-counter medications are inherently safe; diphenhydramine can cause life-threatening arrhythmias in overdose. 2, 5, 3, 4, 6
• Do not overlook electrolyte monitoring in patients on diuretics; hypokalemia and hypomagnesemia are the most common reversible contributors to acquired long QT syndrome. 8
• Do not combine NyQuil with other QT-prolonging agents (macrolides, fluoroquinolones, citalopram, ondansetron) without checking interactions on crediblemeds.org. 8
• Do not use amiodarone or procainamide for ventricular arrhythmias when QT is prolonged; they exacerbate torsades de pointes. 8